海思科(002653.SZ):國家藥監局批准環泊酚注射液上市
格隆匯 12 月 14日丨海思科(002653.SZ)公佈,公司於2020年12月14日從國家藥品監督管理局(“國家藥監局”)網站獲悉“國家藥監局批准環泊酚注射液上市”(相關網址如下:https://www.nmpa.gov.cn/yaowen/ypjgyw/20201214100345170.html),具體內容為:
“近日,國家藥品監督管理局通過優先審評審批程序批准遼寧海思科製藥有限公司申報的1類創新藥環泊酚注射液(商品名:思舒寧)上市。該藥為我國自主研究並擁有自主知識產權的創新藥,用於消化道內鏡檢查中的鎮靜。
環泊酚為GABAA受體激動劑,為麻醉鎮靜藥。該品種上市為患者提供了新的治療選擇。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.